AU1043201A - Cyclosporin formulation - Google Patents

Cyclosporin formulation

Info

Publication number
AU1043201A
AU1043201A AU10432/01A AU1043201A AU1043201A AU 1043201 A AU1043201 A AU 1043201A AU 10432/01 A AU10432/01 A AU 10432/01A AU 1043201 A AU1043201 A AU 1043201A AU 1043201 A AU1043201 A AU 1043201A
Authority
AU
Australia
Prior art keywords
cyclosporin formulation
cyclosporin
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10432/01A
Inventor
Geena Malhotra
Vinay G. Nayak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN1999/000062 external-priority patent/WO2001032143A1/en
Priority claimed from GB0012816A external-priority patent/GB2362573A/en
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of AU1043201A publication Critical patent/AU1043201A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU10432/01A 1999-11-02 2000-10-27 Cyclosporin formulation Abandoned AU1043201A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
WOIN99/00062 1999-11-02
PCT/IN1999/000062 WO2001032143A1 (en) 1999-11-02 1999-11-02 A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and a process for preparation thereof
GB0012816 2000-05-25
GB0012816A GB2362573A (en) 2000-05-25 2000-05-25 Cyclosporin formulation
PCT/GB2000/004143 WO2001032142A1 (en) 1999-11-02 2000-10-27 Cyclosporin formulation

Publications (1)

Publication Number Publication Date
AU1043201A true AU1043201A (en) 2001-05-14

Family

ID=26244360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10432/01A Abandoned AU1043201A (en) 1999-11-02 2000-10-27 Cyclosporin formulation

Country Status (3)

Country Link
EP (1) EP1227793A1 (en)
AU (1) AU1043201A (en)
WO (1) WO2001032142A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
FR2873923B1 (en) * 2004-08-05 2007-01-12 Gattefosse Holding Sa ANHYDROUS SOLID PARTICLE CONTAINING A LIQUID LIPIDIC COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING SAID PARTICLES
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
EP2380564B1 (en) 2007-04-04 2014-10-22 Sigmoid Pharma Limited An oral pharmaceutical composition
ES2528421T3 (en) * 2008-10-22 2015-02-09 Santen Pharmaceutical Co., Ltd Pharmaceutical composition of better absorption through the intestinal tract
ES2649112T3 (en) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composition comprising drops of oil
IN2012DN00781A (en) 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
BR112017009510A2 (en) 2014-11-07 2017-12-19 Sigmoid Pharma Ltd compositions comprising cyclosporine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
KR0146671B1 (en) * 1994-02-25 1998-08-17 김충환 Cyclosporin-containing powder composition
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
WO1998040051A1 (en) * 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
ID25908A (en) * 1998-03-06 2000-11-09 Novartis Ag EMULSION PRACTONCENTRATES CONTAINING CYCLOSPORINE OR MACROLIDES

Also Published As

Publication number Publication date
EP1227793A1 (en) 2002-08-07
WO2001032142A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AU3243300A (en) Multiparticulate formulation
AUPP970099A0 (en) Concrete formulation
AU7998900A (en) Automotive-ceiling-mounted monitor
AU1173201A (en) Skin-gripper
EG24226A (en) Formulation
AU4328800A (en) Pharmaceutical formulation
AU1043201A (en) Cyclosporin formulation
AUPQ147699A0 (en) Sunscreen formulations
AU2792700A (en) Pharmaceutical composition containing cyclosporin
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
AU2804600A (en) Arylaminoalkylamides
AU2023701A (en) Sketcher
AU2699800A (en) Organoceramics
AU3303300A (en) Cleaning formulation
AU3191100A (en) Ligand-bonded complex
AU3839900A (en) Pharmaceutical formulation
AU4081300A (en) Centroid integration
AU3930399A (en) Cyclosporin preparations
GB9927614D0 (en) Sterliant formulation
AU1901801A (en) Glucofuranoses
AU1388501A (en) Pharmaceutical formulation
AU2582200A (en) Windturbine
AU1915601A (en) Periotome
AU2197301A (en) Microlamp

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase